A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment

被引:33
作者
Fuerst, R. [1 ]
Vollmar, A. M. [2 ]
机构
[1] Goethe Univ Frankfurt, Inst Pharmaceut Biol, Bioctr, D-60438 Frankfurt, Germany
[2] Univ Munich, Ctr Drug Res, Dept Pharm, D-81377 Munich, Germany
来源
PHARMAZIE | 2013年 / 68卷 / 07期
关键词
VASCULAR DISRUPTING AGENTS; TAXOL-INDUCED APOPTOSIS; BCL-2; PROTEIN; CELL-DEATH; RAF-1/BCL-2; PHOSPHORYLATION; THERAPEUTIC INTERVENTION; ENDOTHELIAL-CELLS; MARINE COMPOUND; LEUKEMIA-CELLS; SPONGISTATIN;
D O I
10.1691/ph.2013.6509
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Microtubule-targeting agents (MTAs) are the most frequently used anti-cancer drugs. They can be divided into tubulin stabilizing and destabilizing agents. Their mode of action has been ascribed to their ability to interfere with the spindle apparatus and, thus, to block mitosis leading to tumor cell death. However, this view has been challenged in the last years and it became increasingly evident that non-mitotic actions of MTAs, i.e. their ability to affect the dynamics of interphase microtubules, are the most relevant mechanism underlying their efficacy. In this review we are presenting a distinct selection of examples of studies describing biological effects of MTAs in three areas: (i) mitosis-independent cell death and metastasis, (ii) tumor angiogenesis, and (iii) vascular-disrupting activity.
引用
收藏
页码:478 / 483
页数:6
相关论文
共 55 条
[1]   The Bcl-2 protein family [J].
Antonsson, B ;
Martinou, JC .
EXPERIMENTAL CELL RESEARCH, 2000, 256 (01) :50-57
[2]  
Belotti D, 1996, CLIN CANCER RES, V2, P1843
[3]   Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton [J].
Bijman, Marcel N. A. ;
van Nieuw Amerongen, Geerten P. ;
Laurens, Nancy ;
van Hinsbergh, Victor W. M. ;
Boven, Epie .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (09) :2348-2357
[4]   Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells [J].
Blagosklonny, MV ;
Chuman, Y ;
Bergan, RC ;
Fojo, T .
LEUKEMIA, 1999, 13 (07) :1028-1036
[5]  
Blagosklonny MV, 1997, CANCER RES, V57, P130
[6]  
Blagosklonny MV, 1996, CANCER RES, V56, P1851
[7]   VASCULAR OCCLUSION AND TUMOR-CELL DEATH [J].
DENEKAMP, J ;
HILL, SA ;
HOBSON, B .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (02) :271-275
[8]   Matrix metalloproteinases and tumor metastasis [J].
Deryugina, EI ;
Quigley, JP .
CANCER AND METASTASIS REVIEWS, 2006, 25 (01) :9-34
[9]   Combretastatin A4 Phosphate Induces Programmed Cell Death in Vascular Endothelial Cells [J].
Ding, Xueqiang ;
Zhang, Zhaoqiang ;
Li, Su ;
Wang, Anxun .
ONCOLOGY RESEARCH, 2011, 19 (07) :303-309
[10]  
Estève MA, 2007, CURR CANCER DRUG TAR, V7, P713